<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Earnings Report on FinanClub</title>
    <link>https://finan.club/tags/earnings-report/</link>
    <description>Recent content in Earnings Report on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 16 Feb 2024 09:03:20 +0000</lastBuildDate><atom:link href="https://finan.club/tags/earnings-report/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CRSP</title>
      <link>https://finan.club/us/crsp/</link>
      <pubDate>Fri, 16 Feb 2024 09:03:20 +0000</pubDate>
      
      <guid>https://finan.club/us/crsp/</guid>
      <description>score:31
Chances: CRISPR Therapeutics has shown improving price performance, earning an upgrade to its IBD Relative Strength Rating. The company is focused on creating transformative gene-based medicines for serious diseases, and has announced conditional marketing authorization for its gene edited therapy, CASGEVY. Risks: The company doesn&amp;rsquo;t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.</description>
    </item>
    
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 06 Feb 2024 09:06:04 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:126
Chances: Merck &amp;amp; Co. has demonstrated its commitment to expanding its animal health business through the recent acquisition of Elanco&amp;rsquo;s aqua business. The company&amp;rsquo;s strong earnings report and solid guidance indicate that it is well-positioned to thrive despite potential challenges such as the expiration of its patent on Keytruda.</description>
    </item>
    
  </channel>
</rss>
